Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 12

1.

NF-κB suppresses apoptosis and promotes bladder cancer cell proliferation by upregulating survivin expression in vitro and in vivo.

Cui X, Shen D, Kong C, Zhang Z, Zeng Y, Lin X, Liu X.

Sci Rep. 2017 Jan 31;7:40723. doi: 10.1038/srep40723.

PMID:
28139689
2.

Inhibition of PHLPP2/cyclin D1 protein translation contributes to the tumor suppressive effect of NFκB2 (p100).

Xu J, Wang Y, Hua X, Xu J, Tian Z, Jin H, Li J, Wu XR, Huang C.

Oncotarget. 2016 Jun 7;7(23):34112-30. doi: 10.18632/oncotarget.8746.

PMID:
27095572
3.

DMA(V) in Drinking Water Activated NF-κB Signal Pathway and Increased TGF-β and IL-1β Expressions in Bladder Epithelial Cells of Rats.

Cao S, Liu S, Wang F, Liu J, Li M, Wang C, Xi S.

Mediators Inflamm. 2015;2015:790652. doi: 10.1155/2015/790652.

PMID:
26617437
4.

Down-regulation of NF kappa B activation is an effective therapeutic modality in acquired platinum-resistant bladder cancer.

Ito Y, Kikuchi E, Tanaka N, Kosaka T, Suzuki E, Mizuno R, Shinojima T, Miyajima A, Umezawa K, Oya M.

BMC Cancer. 2015 Apr 29;15:324. doi: 10.1186/s12885-015-1315-9.

PMID:
25926105
5.

To be an ally or an adversary in bladder cancer: the NF-κB story has not unfolded.

Mukherjee N, Houston TJ, Cardenas E, Ghosh R.

Carcinogenesis. 2015 Mar;36(3):299-306. doi: 10.1093/carcin/bgu321. Review.

PMID:
25543121
6.

Thrombomodulin expression regulates tumorigenesis in bladder cancer.

Wu CT, Chang YH, Lin P, Chen WC, Chen MF.

BMC Cancer. 2014 May 28;14:375. doi: 10.1186/1471-2407-14-375.

PMID:
24886404
7.

Fibroblast growth factor receptor 3 interacts with and activates TGFβ-activated kinase 1 tyrosine phosphorylation and NFκB signaling in multiple myeloma and bladder cancer.

Salazar L, Kashiwada T, Krejci P, Meyer AN, Casale M, Hallowell M, Wilcox WR, Donoghue DJ, Thompson LM.

PLoS One. 2014 Jan 23;9(1):e86470. doi: 10.1371/journal.pone.0086470.

PMID:
24466111
8.

HAF drives the switch of HIF-1α to HIF-2α by activating the NF-κB pathway, leading to malignant behavior of T24 bladder cancer cells.

Guan Z, Ding C, Du Y, Zhang K, Zhu JN, Zhang T, He D, Xu S, Wang X, Fan J.

Int J Oncol. 2014 Feb;44(2):393-402. doi: 10.3892/ijo.2013.2210.

PMID:
24316875
9.

Inflammatory pathways as promising targets to increase chemotherapy response in bladder cancer.

Zhu Z, Shen Z, Xu C.

Mediators Inflamm. 2012;2012:528690. doi: 10.1155/2012/528690. Review.

PMID:
22811589
10.

ErbB2 and NFκB overexpression as predictors of chemoradiation resistance and putative targets to overcome resistance in muscle-invasive bladder cancer.

Koga F, Yoshida S, Tatokoro M, Kawakami S, Fujii Y, Kumagai J, Neckers L, Kihara K.

PLoS One. 2011;6(11):e27616. doi: 10.1371/journal.pone.0027616.

PMID:
22102915
11.

Coordinated increased expression of Cyclooxygenase2 and nuclear factor κB is a steady feature of urinary bladder carcinogenesis.

Kontos S, Sotiropoulou-Bonikou G, Kominea A, Melachrinou M, Balampani E, Bonikos D.

Adv Urol. 2010. pii: 871356. doi: 10.1155/2010/871356.

PMID:
20827306
12.

Inflammation and cancer: how friendly is the relationship for cancer patients?

Aggarwal BB, Gehlot P.

Curr Opin Pharmacol. 2009 Aug;9(4):351-69. doi: 10.1016/j.coph.2009.06.020. Review.

PMID:
19665429
Items per page

Supplemental Content

Support Center